Physician profile
Scott Kruger
NPI 1376548057
$1,556.63
in general payments reported to CMS, 2019-2025
16 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $26.58 · 2021: $162 · 2022: $147 · 2023: $511 · 2024: $37.54 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468 · Education: $424 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.42 |
| Education | $424.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $243.48 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $208.69 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $185.90 | 2022-2023 | |
| Astellas Pharma US INC | $184.94 | 2023 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Array Biopharma INC | $150.00 | 2025 | Braftovi, Lorbrena, Mektovi |
| Sobi, INC | $125.00 | 2023 | |
| Lilly USA, LLC | $115.58 | 2023 | |
| Daiichi Sankyo INC. | $79.03 | 2025 | Enhertu |
| Seagen INC. | $38.51 | 2019-2022 | |
| Genentech USA, INC. | $19.37 | 2025 | Lunsumio |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Onivyde |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2019 | |
| Csl Behring | $13.46 | 2025 | Hizentra |
| Foundation Medicine, INC. | $11.26 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kruger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.